(Q24234491)

https://api.crossref.org/works/10.1002%2F14651858.CD008150.PUB2

Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008150.PUB2

Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008150.PUB2

A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008150.PUB2

Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008150.PUB2

Q10 therapy in patients with idiopathic Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008150.PUB2

Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008150.PUB2

Criteria for diagnosing Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008150.PUB2

Biochemical functions of coenzyme Q10

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008150.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008150.PUB2

The coenzyme Q10 status of the brain regions of Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008150.PUB2

Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008150.PUB2

Role of coenzyme Q10 (CoQ10) in cardiac disease, hypertension and Meniere-like syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008150.PUB2

Parkinson's disease. First of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008150.PUB2

Enrichment of coenzyme Q10 in plasma and blood cells: defense against oxidative damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008150.PUB2

Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008150.PUB2

Therapeutic role of coenzyme Q(10) in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008150.PUB2

Parkinson's prevalence estimated by a state registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008150.PUB2

Systematic review of incidence studies of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008150.PUB2

Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008150.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension

1 reference

COCI

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD008150.PUB2

Measuring inconsistency in meta-analyses

9 February 2024

1 reference

COCI

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD008150.PUB2